TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35242798
Drug: Nutrient formulation
Normalized name: Votrient
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Nutrient formulation containing DHA, ARA, iron, vitamin B12, folic acid, and sphingomyelin from whey protein concentrate
Study: 35243302
Drug: High-dose sevelamer
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose sevelamer (800 mg thrice daily, titratable up to 1,200 mg thrice daily)
Study: 35243302
Drug: Low-dose sevelamer
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose sevelamer (400 mg thrice daily) with calcium carbonate
Study: 35243302
Drug: High-dose sevelamer
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose sevelamer
Study: 35243302
Drug: Low-dose sevelamer
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose sevelamer
Study: 35243320
Drug: Booster CD-JEV
Normalized name: Jevtana
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Booster CD-JEV dose
Study: 35244681
Drug: TAA-T infusions
Normalized name: T-5224
DrugBank: T-5224 (DB05998)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAA-T infusions at doses of 0.5 to 4 × 10^7/m2
Study: 35244681
Drug: TAA-T infusions
Normalized name: T-5224
DrugBank: T-5224 (DB05998)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAA-T infusions
Study: 35244820
Drug: Daily ECG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily ECG TTM (30 s recordings)
Study: 35244820
Drug: Daily ECG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily ECG TTM
Study: 35245341
Drug: Solid formulation
Normalized name: Corydalis solida whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solid formulation of Vitamin B12 delivered during breastfeeding
Study: 35245341
Drug: Solid formulation
Normalized name: Corydalis solida whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solid formulation of Vitamin B12
Study: 35246776
Drug: rhIL-7 ex
Normalized name: rhIL-7-hyFc
DrugBank: Efineptakin alfa (DB16395)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIL-7 ex vivo administration
Study: 35247086
Drug: Vorolanib 300
Normalized name: Vorolanib
DrugBank: Vorolanib (DB15247)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorolanib 300 mg orally once daily plus pembrolizumab
Study: 35247086
Drug: Vorolanib 300
Normalized name: Vorolanib
DrugBank: Vorolanib (DB15247)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorolanib 300 mg orally once daily plus nivolumab
Study: 35247086
Drug: Vorolanib 400
Normalized name: Vorolanib
DrugBank: Vorolanib (DB15247)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorolanib 400 mg orally once daily
Study: 35247086
Drug: Vorolanib 300
Normalized name: Vorolanib
DrugBank: Vorolanib (DB15247)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorolanib 300 mg orally once daily
Study: 35247086
Drug: Vorolanib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorolanib (300 or 400 mg)
Study: 35247274
Drug: Pexidartinib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pexidartinib (200 mg single dose) in subjects with mild hepatic impairment
Study: 35247274
Drug: Pexidartinib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pexidartinib (200 mg single dose) in subjects with moderate hepatic impairment
Study: 35247913
Drug: Lenalidomide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide (25 mg as the recommended phase II dose, taken orally for 21 consecutive days of 28-day cycles)
Study: 35248212
Drug: Sofosbuvir-velpatasvir-voxilaprevir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir-velpatasvir-voxilaprevir (400 mg sofosbuvir, 100 mg velpatasvir, 100 mg voxilaprevir) once daily for 12 weeks
Study: 35248213
Drug: Sofosbuvir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir (400 mg) and Velpatasvir (100 mg) once-daily for 12 weeks
Study: 35248647
Drug: PDS 10
Normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PDS 10 mg/mL
Study: 35248647
Drug: PDS 40
Normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PDS 40 mg/mL
Study: 39209113
Drug: PDS 100
Normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PDS 100 mg/mL
Study: 35248866
Drug: FCN-411 (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCN-411 (4 mg, 8 mg, 12 mg, and 16 mg once daily until maximum tolerated dose)
Study: 35248866
Drug: FCN-411 (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCN-411 (8 mg once daily, recommended phase II dose)
Study: 35248866
Drug: FCN-411 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCN-411 (all doses)
Study: 35249485
Drug: AAV9-coGLB1 gene
Normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: AAV9-coGLB1 gene therapy, injected via caudal vein at 4 weeks of age, sustained expression for up to 32 weeks.
Study: 35249540
Drug: Pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological treatment for ADHD symptoms (specific medication not detailed)
Study: 35249706
Drug: Propofol administered
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol administered via target-controlled infusion
Study: 35250870
Drug: rhIGF-1 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIGF-1 treatment
Study: 35251038
Drug: Reduction in
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduction in GLI activity by small molecule inhibitors or shRNA-mediated knockdown of GLI1 or GLI2.
Study: 35251315
Drug: Cisplatin 75
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 75 mg/m² in combination with everolimus
Study: 35251320
Drug: Ribociclib +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribociclib + endocrine therapy (ET)
Study: 35251346
Drug: Tinzaparin administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinzaparin administered at an intermediate dose (8,000-12,000 Anti-Xa IU; once daily)
Study: 35251346
Drug: Tinzaparin administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinzaparin administered at a prophylactic dose (≤4,500 Anti-Xa IU; once daily)
Study: 35251346
Drug: Tinzaparin (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinzaparin (both doses)
Study: 35253296
Drug: Information before
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Information before rectal cancer surgery
Study: 35253361
Drug: Defibrotide 6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defibrotide 6.25 mg/kg IV q6h from the day prior to conditioning through day +21
Study: 35253361
Drug: Defibrotide 6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defibrotide 6.25 mg/kg IV q6h
Study: 35253443
Drug: Oral antithrombotic
Normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antithrombotic agents
Study: 35254415
Drug: Taminadenant (80-640
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taminadenant (80-640 mg, orally, twice a day)
Study: 35254415
Drug: Taminadenant (80-640
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taminadenant (80-640 mg, orally, twice a day) with spartalizumab (400 mg, i.v., every 4 weeks)
Study: 35254416
Drug: INCB086550 (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB086550 (a small-molecule PD-L1 inhibitor)
Study: 35255140
Drug: CoronaVac vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoronaVac vaccine (2 doses, 8-12 weeks before enrollment)
Study: 38381948
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral pre-exposure prophylaxis (PrEP)
Study: 35256316
Drug: MF-directed monotherapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF-directed monotherapy (hydroxyurea or ruxolitinib)
Study: 35256525
Drug: No lipid-lowering
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: No lipid-lowering treatment
Study: 35256693
Drug: Thionamide anti-thyroid
Normalized name: Thyroid
DrugBank: Thyroid, porcine (DB09100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thionamide anti-thyroid drug (titration dosing regimen)
Study: 35256844
Drug: Treatment preferences
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment preferences based on avoiding severe nerve damage and longer progression-free survival (PFS)
Study: 35256844
Drug: Cost implications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost implications on treatment preferences
Study: 35257639
Drug: Combined isoflavone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined isoflavone compound (CIC)
Study: 35257949
Drug: Afatinib 40
Normalized name: afatinib 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib 40 mg/30 mg once daily with pembrolizumab 200 mg every 3 weeks
Study: 35258804
Drug: Pre-implant assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-implant assessment
Study: 35258804
Drug: Post-implant assessment
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-implant assessment
Study: 35258841
Drug: Oral semaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral semaglutide 14 mg daily
Study: 35258987
Drug: Temozolomide followed
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide followed by low-dose ipilimumab and nivolumab
Study: 35259629
Drug: Waiting neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting neoadjuvant chemotherapy in resectable tumours during lockdown
Study: 35259629
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of mFOLFIRINOX preoperative chemotherapy regimen during lockdown
Study: 35260030
Drug: Exposure based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure based cognitive behavioral therapy (ECBT)
Study: 35260178
Drug: Implantable ultrasound
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implantable ultrasound device (SonoCloud-1) with 1-MHz frequency, used in combination with intravenous infusion of microbubbles, administered over 3.5 months with seven ultrasound sessions (twice per month).
Study: 35260458
Drug: VAC52150 (Ad26.ZEBOV,
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAC52150 (Ad26.ZEBOV, MVA-BN-Filo) two-dose vaccine regimen, doses given 56 days apart.
Study: 35260458
Drug: Delayed second
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed second dose of VAC52150 (Ad26.ZEBOV, MVA-BN-Filo) vaccine.
Study: 35260879
Drug: ABBV-085 antibody-drug
Normalized name: antibody-drug conjugate DP303c
DrugBank: DP-303c (DB17212)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABBV-085 antibody-drug conjugate (ADC)
Study: 35260913
Drug: Bevacizumab 10
Normalized name: bevacizumab 100 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab 10 mg/kg on days 1 and 15, Irinotecan 125 mg/m²
Study: 35260962
Drug: Induced Hypertension
Normalized name: INVESTIGATIONAL ANTI-HYPERTENSIVE DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induced Hypertension (iHTN) via norepinephrine infusion in 20-mm Hg increments
Study: 35484319
Drug: Avelumab 20
Normalized name: avelumab 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avelumab 20 mg/kg intravenously every 2 weeks
Study: 35262846
Drug: Milvexian 60
Normalized name: Milvexian
DrugBank: Milvexian (DB16233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milvexian 60 mg
Study: 35263188
Drug: Extended Infusion
Normalized name: Extended Infusion Set 6mm Cannula 23" Tubing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended Infusion Set
Study: 35263963
Drug: filgotinib 100
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: filgotinib 100 mg
Study: 35264341
Drug: Surgical treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatments for AEDH (including craniotomy and DC)
Study: 35264424
Drug: sNfL levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: sNfL levels at preataxic stage (median 15.5 pg/mL [interquartile range 10.5-21.1 pg/mL])
Study: 35264424
Drug: sNfL levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: sNfL levels at ataxic stage (31.6 pg/mL [26.2-37.7 pg/mL])
Study: 35264424
Drug: sNfL levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: sNfL levels in controls (6.0 pg/mL [4.7-8.6 pg/mL])
Study: 35264434
Drug: Ziv-aflibercept 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziv-aflibercept 4 mg/kg plus pembrolizumab 2 mg/kg every 2 weeks
Study: 35264559
Drug: ImmunoPET imaging
Normalized name: triclosan
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ImmunoPET imaging using a radiolabeled HIV Env-specific broadly neutralizing antibody
Study: 35266046
Drug: Energy drink
Normalized name: Boost Energy Drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy drink (240 mg caffeine)
Study: 35266046
Drug: Coffee (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coffee (240 mg caffeine)
Study: 35266065
Drug: Quantum Magnetic
Normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quantum Magnetic Resonance Therapy (QMRT)
Study: 35266624
Drug: Sustained virological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained virological response (SVR-12) with direct-acting antiviral agents (DAAs)
Study: 35266655
Drug: Topical recombinant
Normalized name: thrombin topical recombinant 5000 intl units topical powder for reconstitution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical recombinant nerve growth factor (cenegermin)
Study: 35267143
Drug: Perceiving negative
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perceiving negative interferences of cancer in daily life
Study: 35267535
Drug: Multitask learning
Normalized name: Noxzema Clean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multitask learning of pre-/mid-treatment FDG-PET radiomics
Study: 35267579
Drug: 13.56 MHz
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13.56 MHz modulated electro-hyperthermia (mEHT) boost during neoadjuvant treatment, twice a week during radiotherapy
Study: 35268478
Drug: Colchicine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (1 mg) administered 24 hours before surgery and on days 2, 3, 4, and 5 postoperatively.
Study: 35268478
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered on the same schedule as colchicine.
Study: 35270262
Drug: CoVQuest-CC Questionnaire
Normalized name: FORMIC ACID 14.5 g in 100 g TOPICAL GEL [Provita Konquest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoVQuest-CC Questionnaire
Study: 35272132
Drug: Cabazitaxel (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabazitaxel (25 mg/m² administered intravenously)
Study: 35272845
Drug: Mobility, nutrition,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobility, nutrition, medication use, physical functioning, and self-rated health before surgery.
Study: 35272946
Drug: Cancer drug
Normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cancer drug repurposing for PIK3CA-driven overgrowth
Study: 35274209
Drug: Continuous wound
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous wound infusion combined with intrathecal morphine
Study: 35274209
Drug: Continuous wound
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous wound infusion alone
Study: 35274717
Drug: Pembrolizumab in
Normalized name: pembrolizumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab in combination with capecitabine and oxaliplatin (CAPOX)
Study: 35274722
Drug: D-0316 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-0316 (50 mg)
Study: 35274722
Drug: D-0316 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-0316 (100 mg)
Study: 35275019
Drug: Dynamic gallium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic gallium 68 imaging (details on dosage and duration not provided)
Study: 35275108
Drug: DEPITAC questionnaire
Normalized name: TAPE,SILICONE MEPITAC 0.75INX3YD #298300
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEPITAC questionnaire administered by nurses
Study: 35275599
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy (ART) initiated in Fiebig 1 acute HIV infection
Study: 35275599
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy (ART) initiated in later Fiebig stages
Study: 35275734
Drug: Father-focused childhood
Normalized name: Gallus gallus feather
DrugBank: Gallus gallus feather (DB10420)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Father-focused childhood obesity prevention program, details on dosage and duration not available
Study: 35276694
Drug: Multi-kinase/PDGFRβ inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-kinase/PDGFRβ inhibitors
Study: 35276694
Drug: HDAC inhibitors
Normalized name: Hdac inhibitor cxd101
DrugBank: CXD101 (DB16182)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDAC inhibitors
Study: 35277389
Drug: Third dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third dose of CoronaVac vaccine
Study: 35279084
Drug: Historical control
Normalized name: typhus, historical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Historical control (standard-of-care antibiotics)
Study: 35279143
Drug: 0.25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/kg single-dose primaquine
Study: 35279152
Drug: Carboplatin/paclitaxel (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin/paclitaxel (standard of care chemotherapy)
Study: 35279152
Drug: MYC/MAX dimerization
Approvals — FDA: no, EMA: no, PMDA: no
Description: MYC/MAX dimerization inhibitor (10058-F4)
Study: 35279271
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg pembrolizumab intravenously every 3 weeks for 6 months (eight cycles)
Study: 35279811
Drug: Rituximab (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (375 mg/m²) administered as four weekly intravenous infusions
Study: 35280363
Drug: Pembrolizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (200 mg) combined with paclitaxel (135 mg) and cisplatin as neoadjuvant therapy.
Study: 35280363
Drug: Neoadjuvant chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemoradiotherapy (nCRT) as the standard treatment under NCCN guidelines.
Study: 35280802
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (NAC) regimens
Study: 35280802
Drug: SOXA (apatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOXA (apatinib in combination with S-1 and oxaliplatin) cohort
Study: 35281856
Drug: Vismodegib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vismodegib (150 mg orally once a day for a 21-day cycle)
Study: 35282037
Drug: Apatinib mesylate
Normalized name: mesylate
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib mesylate (500 mg qd) plus pemetrexed (500 mg/m2)
Study: 35282136
Drug: Hetrombopag (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hetrombopag (5 mg orally once daily for up to 6 weeks)
Study: 35283104
Drug: benralizumab (30-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: benralizumab (30-mg subcutaneous dose)
Study: 35283460
Drug: Alternative dosing
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative dosing forms of hydrocortisone
Study: 35283460
Drug: Corticotropin-releasing hormone
Normalized name: corticotropin-releasing hormone
DrugBank: Corticorelin (DB05394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticotropin-releasing hormone receptor antagonists
Study: 35283460
Drug: Androgen biosynthesis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen biosynthesis inhibitors
Study: 35283460
Drug: Gene therapy
Normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene therapy vector
Study: 35283693
Drug: Prostate-specific membrane
Normalized name: Recombinant soluble prostate-specific membrane antigen (rsPSMA) vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostate-specific membrane antigen- (PSMA-) targeted radioligand therapy (RLT)
Study: 35285405
Drug: Hypofractionated radiotherapy
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypofractionated radiotherapy (HF-RT) with nodal simultaneous integrated boost (nSIB) at a dose of 2.67 Gy x 15 fractions
Study: 38320431
Drug: Dose-limiting toxicity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-limiting toxicity (DLT)
Study: 35285484
Drug: Panitumumab, chemotherapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panitumumab, chemotherapy, and external beam radiation therapy
Study: 35285786
Drug: Fostemsavir 600
Normalized name: fostemsavir 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fostemsavir 600 mg BID for 4 days
Study: 35285786
Drug: Maraviroc 300
Normalized name: maraviroc 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maraviroc 300 mg BID for 5 days
Study: 35285786
Drug: Fostemsavir 600
Normalized name: fostemsavir 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fostemsavir 600 mg BID with Maraviroc 300 mg BID for 7 days
Study: 35286612
Drug: Topical/traditional systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical/traditional systemic agents
Study: 35287469
Drug: Cabozantinib 60
Normalized name: cabozantinib 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib 60 mg once daily administered orally
Study: 35287613
Drug: nab-paclitaxel 260
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel 260 mg/m²
Study: 35287672
Drug: Sandoz biosimilar
Normalized name: CLOZAPINE (SANDOZ)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sandoz biosimilar filgrastim (twice-daily)
Study: 35287719
Drug: Higher adrenaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher adrenaline dose during cardiopulmonary resuscitation
Study: 35287719
Drug: Previous proton
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous proton pump inhibitor use
Study: 37118832
Drug: Autologous bone
Normalized name: Human autologous bone marrow derived osteoblastic cells
DrugBank: Human autologous bone marrow derived osteoblastic cells (DB18259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous bone marrow mononuclear cell (BMMNC) infusion